Terminal sugars of Fc glycans influence antibody effector functions of IgGs

Current Opinion in Immunology

Volumn 20, Issue 4, 2008, Pages 471-478

  Raju, T Shantha ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CARBOHYDRATE; CD16 ANTIGEN; COMPLEMENT COMPONENT C1Q; FC RECEPTOR; FUCOSE; GALACTOSE; GLYCAN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; MANNOSE; N ACETYLGLUCOSAMINE; SIALIC ACID;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CHROMATOGRAPHY; ENZYME ACTIVITY; HUMAN; MOLECULAR INTERACTION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; SIALYLATION; STRUCTURE ANALYSIS;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; POLYSACCHARIDES;

EID: 48549090941     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.06.007     Document Type: Review

References (52)

1. Beale D., and Feinstein A. Structure and function of the constant regions of immunoglobulins. Q Rev Biophys 9 (1976) 135-180
2. Raju T.S. Glycosylation variations with expression systems and their impact on biological activity of therapeutic immunoglobulins. Bioprocess Int 1 (2003) 44-53
3. Wright A., and Morrison S.L. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol 15 (1997) 26-32
4. Ryan M.H., Petrone D., Nemeth J.F., Barnathan E., Björck L., and Jordan R.E. Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid. Mol Immunol 45 (2008) 1837-1846. Proteases that cleave IgGs in vivo thus making them unable to elicit effector functions.
5. Raju T.S., and Scallon B.J. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem Biophys Res Commun 341 (2006) 797-803. Aglycosylated or deglycosylated IgGs in the Fc are more sensitive to proteases.
6. Raju T.S., and Scallon B. Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain. Biotechnol Prog 33 (2007) 964-971. Terminal-sugar residues of Fc glycans also affect the antibody stability.
7. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 7 (2007) 1401-1413
8. Nimmerjahn F., and Ravetch J.V. Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 8 (2008) 34-47
9. Raju T.S., Briggs J.B., Borge S.M., and Jones A.J. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10 (2000) 477-486
10. Mizuochi T., Taniguchi T., Shimizu A., and Kobata A. Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J Immunol 129 (1982) 2016-2020
11. Hamako J., Matsui T., Ozeki Y., Mizuochi T., and Titani K. Comparative studies of asparagine-linked sugar chains of immunoglobulin G from eleven mammalian species. Comp Biochem Physiol B 106 (1993) 949-954
12. Mimura Y., Ghirlando R., Sondermann P., Lund J., and Jefferis R. The molecular specificity of IgG-Fc interactions with Fc gamma receptors. Adv Exp Med Biol 495 (2001) 49-53
13. Yamada E., Tsukamoto Y., Sasaki R., Yagyu K., and Takahashi N. Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconj J 14 (1997) 401-405
14. Alavi A., and Axford J. Evaluation of beta 1,4-galactosyltransferase in rheumatoid arthritis and its role in the glycosylation network associated with this disease. Glycoconj J 12 (1995) 206-210
15. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., and Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25 (2007) 21-50
16. Kobata A.A. Journey to the world of glycobiology. Glycoconj J 17 (2000) 443-464
17. Hodoniczky J., Zheng Y.Z., and James D.C. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 21 (2005) 1644-1652
18. Jones A.J., Papac D.I., Chin E.H., Keck R., Baughman S.A., Lin Y.S., Kneer J., and Battersby J.E. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 17 (2007) 529-540. Terminal GlcNAc residues on glycoproteins cause selective clearance because of their ability to bind to the mannose receptor in the liver.
19. Malhotra R., Wormald M.R., Rudd P.M., Fischer P.B., Dwek R.A., and Sim R.B. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1 (1995) 237-243
20. Miyoshi E., Noda K., Yamaguchi Y., Inoue S., Ikeda Y., Wang W., Ko J.H., Uozumi N., Li W., and Taniguchi N. The alpha1-6-fucosyltransferase gene and its biological significance. Biochim Biophys Acta 1473 (1999) 9-20
21. Shields R.L., Lai J., Keck R., Connell L.Y., Hong K., Meng Y.G., Weikert S.H., and Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277 (2002) 26733-26740. Nonfucosylation of IgGs increases their binding affinity to FcγRIIIa and therefore increases ADCC activity.
22. Satoh M., Iida S., and Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 6 (2006) 1161-1173
23. Mimura Y., Lund J., Church S., Dong S., Li J., Goodall M., and Jefferis R. Butyrate increases production of human chimeric IgG in CHO-K1 cells whilst maintaining function and glycoform profile. J Immunol Methods 247 (2001) 205-216
24. Imai-Nishiya H., Mori K., Inoue M., Wakitani M., Iida S., Shitara K., and Satoh M. Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnol 7 (2007) 84
25. Patnaik S.K., and Stanley P. Lectin-resistant CHO glycosylation mutants. Methods Enzymol 416 (2006) 159-182
26. Umana P., Jean M., Moudry R., Amstutz H., and Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17 (1999) 176-180
27. Davies J., Jiang L., Pan L.Z., LaBarre M.J., Anderson D., and Reff M. Expression of GnT-III in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for Fc gamma RIII. Biotechnol Bioeng 74 (2001) 288-294
28. Schuster M., Umana P., Ferrara C., Brünker P., Gerdes C., Waxenecker G., Wiederkum S., Schwager C., Loibner H., Himmler G., et al. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res 65 (2005) 7934-7941
29. Ferrara C., Brünker P., Suter T., Moser S., Püntener U., and Umaña P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng 93 (2006) 851-861
30. Niwa R., Natsume A., Uehara A., Wakitani M., Iida S., Uchida K., Satoh M., and Shitara K. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 306 (2005) 151-160. Increased ADCC activity and improved binding to the FcγRIIIa receptor of nonfucosylated IgGs is independent of subclass.
31. Scallon B., McCarthy S., Radewonuk J., Cai A., Naso M., Raju T.S., and Capocasale R. Quantitative in vivo comparisons of the Fc gamma receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody. Int Immunopharmacol 7 (2007) 761-772
32. Varki A. "Unusual" modifications and variations of vertebrate oligosaccharides: are we missing the flowers for the trees?. Glycobiology 6 (1996) 707-710
33. Scallon B.J., Tam S.H., McCarthy S.G., Cai A.N., and Raju T.S. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44 (2007) 1524-1534. Increased sialylation results in decreased ADCC activity, because of decreased binding to FcγRIIIa receptor.
34. Kaneko Y., Nimmerjahn F., and Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006) 670-673. Antibody sialylation influences the anti-inflammatory activity but reduces ADCC activity.
35. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., and Ravetch J.V. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320 (2008) 373-376. α2,6-Linked sialic acid residues act as a switch for anti-inflammatory activity of IVIGs.
36. Raju T.S., Briggs J.B., Chamow S.M., Winkler M.E., and Jones A.J. Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. Biochemistry 40 (2001) 8868-8876
37. Wright A., Sato Y., Okada T., Chang K., Endo T., and Morrison S. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 10 (2000) 1347-1355. Presence of high mannose-type glycans decreases serum half-life of IgGs.
38. Millward T.A., Heitzmann M., Bill K., Langle U., Schumacher P., and Forrer K. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals 36 (2008) 41-47. High mannose-type glycans do not appear to affect the serum half-life of certain IgGs. As a result, the effect of high mannose-type glycans on serum half-life of IgGs is not completely understood.
39. Zhou Q., Shankara S., Roy A., Qiu H., Estes S., McVie-Wylie A., Culm-Merdek K., Park A., Pan C., and Edmunds T. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 99 (2008) 652-665. Mannose residues are shown to affect the ADCC and CDC activities of IgGs.
40. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9 Å and 2.8 Å resolution. Biochemistry 20 (1981) 2361-2370
41. Krapp S., Mimura Y., Jefferis R., Huber R., and Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325 (2003) 979-989. Crystal structure of homogeneous antibody glycoforms reveals the various hydrophobic and hydrophilic interactions between sugar residues and amino acid residues in the Fc.
42. Ghirlando R., Lund J., Goodall M., and Jefferis R. Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. Immunol Lett 68 (1999) 47-52 Influence of terminal sugars on antibody structure is revealed using homogeneous antibody glycoforms.
43. Sauer E., Kleywegt G.J., Uhlen M., and Jones T.A. Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. Structure 3 (1995) 265-278
44. Yamaguchi Y., Kato K., Shindo M., Aoki S., Furusho K., Koga K., Takahashi N., Arata Y., and Shimada I. Dynamics of the carbohydrate chains attached to the Fc portion of immunoglobulin G as studied by NMR spectroscopy assisted by selective 13C labeling of the glycans. J Biomol NMR 12 (1998) 385-394 Interactions of terminal Gal residues with amino acid resides in the Fc were measured using NMR in solutions with 13C labeling.
45. Starovasnik M.A., Braisted A.C., and Wells J.A. Structural mimicry of a native protein by a minimized binding domain. Proc Natl Acad Sci U S A 94 (1997) 10080-10085
46. Tishchenko V.M. Effect of immunoglobulin G1 Pro 290 residue on structural and biological characteristics of its SH2 domain. Bioorg Khim 24 (1998) 465-467
47. Tao M.H., and Morrison S.L. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143 (1989) 2595-2601
48. Varki N.M., and Varki A. Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest 87 (2007) 851-857
49. Raju T.S., and Davidson E.A. Role of sialic acid on the viscosity of canine tracheal mucin glycoprotein. Biochem Biophys Res Commun 205 (1994) 402-409
50. Matsumiya S., Yamaguchi Y., Saito J., Nagano M., Sasakawa H., Otaki S., Satoh M., Shitara K., and Kato K. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol 368 (2007) 767-779. Crystal structure of fucosylated and nonfucosylated Fc fragments reveals minor structural variations in the Fc because of differences in electron density.
51. Ferrara C., Stuart F., Sondermann P., Brünker P., and Umaña P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 281 (2006) 5032-5036. This paper describes the importance of glycosylation of IgGs and receptor molecules for interactive binding.
52. Sinclair A.M., and Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 94 (2005) 1626-1635